BioCardia Files 8-K
Ticker: BCDA · Form: 8-K · Filed: Sep 22, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Sep 22, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
BioCardia filed an 8-K, check for updates.
AI Summary
BioCardia, Inc. filed an 8-K on September 22, 2025, reporting other events and financial statements. The company, formerly known as Tiger X Medical, Inc., is incorporated in Delaware and headquartered in Sunnyvale, California.
Why It Matters
This filing indicates BioCardia, Inc. is making a regulatory submission to the SEC, which could contain important updates on company events or financial performance.
Risk Assessment
Risk Level: low — This is a routine SEC filing without immediate disclosed financial or operational impacts.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- Tiger X Medical, Inc. (company) — Former company name
- September 22, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Sunnyvale, California (location) — Principal executive offices
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' as the items being reported, but the specific details of these events are not provided in the header information.
When was BioCardia, Inc. incorporated?
BioCardia, Inc. was incorporated in Delaware.
What is the principal executive office address for BioCardia, Inc.?
The principal executive offices are located at 320 Soquel Way, Sunnyvale, California 94085.
Has BioCardia, Inc. undergone name changes in the past?
Yes, BioCardia, Inc. was formerly known as Tiger X Medical, Inc. (name change on 20110616), Cardo Medical, Inc. (name change on 20081027), and CLICKNSETTLE COM INC (name change on 20000823).
What is the SIC code for BioCardia, Inc.?
The Standard Industrial Classification (SIC) code for BioCardia, Inc. is 2836, which corresponds to BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 456 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-09-22 08:00:10
Key Financial Figures
- $0.001 B — h registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20250919c_8k.htm (8-K) — 26KB
- ex_863276.htm (EX-99.1) — 8KB
- 0001437749-25-029547.txt ( ) — 164KB
- bcda-20250922.xsd (EX-101.SCH) — 3KB
- bcda-20250922_def.xml (EX-101.DEF) — 11KB
- bcda-20250922_lab.xml (EX-101.LAB) — 15KB
- bcda-20250922_pre.xml (EX-101.PRE) — 11KB
- bcda20250919c_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On September 22, 2025, BioCardia, Inc. issued a press release announcing it has had a positive preliminary clinical consultation with Japan's Pharmaceutical and Medical Devices Agency (PMDA) on the CardiAMP Heart Failure Trial results previously provided to the agency. The meeting was held in preparation for the formal clinical consultation on acceptability of the clinical data for submission of an application for approval. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 BioCardia, Inc. press release dated September 22, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: September 22, 2025